DENMARK/SWITZERLAND - Blackstone-backed Nycomed bids for EUR 4.5bn Solvay
Reports suggest that Nordic Capital- and Blackstone-backed pharmaceuticals business Nycomed has made a takeover approach for the drug division of publicly listed chemical and pharmaceutical company Solvay SA, with the offer thought to be valued at around EUR 4.5bn.
At the time of the deal, the company was based in Denmark and was the region's first 'tertiary buyout'. The transaction financing included the issuance of approximately EUR 400m PIK notes.
Nordic Capital originally acquired Nycomed for approximately EUR 550bn in 1999, providing EUR 120m of expansion capital in mid-2001. In November 2002, DLJ and Blackstone, together with a group of investors including AlpInvest (previously NIB Capital Private Equity), acquired 100% of the shares in the business.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








